In an attempt to lower insulin costs for members who receive prescription drug coverage through Medicare Part D or Medicare Advantage, several plans will limit out-of-pocket costs to a $35 copay. The Centers for Medicare and Medicaid Services (CMS) said this change would make insulin costs more consistent for patients and potentially reduce out-of-pocket costs by hundreds of dollars.
More than 1,750 Medicare Part D and Medicare Advantage plans will include this change in their plans for 2021.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Most Medicare patients choose to enroll in Part D coverage, either through a standalone prescription drug plan or through a Medicare Advantage plan. Roughly 75% of Medicare enrollees had Part D coverage last year, according to CMS.
Medicare Part D plans are divided into four phases. The amount that patients pay toward their prescription fluctuates with each phase.
For example, a patient would pay toward their deductible in the first phase, and would then be responsible for paying 25% of the drug cost before reaching an initial coverage limit, currently set at $4,020. After reaching that threshold, they go into the “coverage gap,” where the patient pays for 25% of the drug price and manufacturers cover most of the cost, before reaching their out-of-pocket limit. CMS estimated the average out-of-pocket cost for insulin each year would be $675 using this structure.
Under the new plan, patients would only pay a $35 copay through each phase, for an estimated out-of-pocket cost of $229.
“This market-based solution, in which insulin manufacturers and Part D sponsors compete to provide lower costs and higher quality for patients, will allow seniors to choose a Part D plan that covers their insulin at an average 66 percent lower out-of-pocket cost throughout the year,” CMS Administrator Seema Verma said in a news release.
As before, pharmaceutical manufacturers will still pay for 70% of insulin costs while patients are in the “coverage gap.” But those payments would be calculated before the application of supplemental benefits.
All three major insulin manufacturers — Eli Lilly, Novo Nordisk and Sanofi-Aventis — will participate in the program.
Photo credit: Hero Images, Getty Images